Mammary tumors initiated by constitutive Cdk2 activation contain an invasive basal-like component

Neoplasia

Volumn 10, Issue 11, 2008, Pages 1240-1252

  Corsino, Patrick E ^a   Davis, Bradley J ^a   Nørgaard, Peter H ^b   Teoh Parker, Nicole N ^a   Law, Mary ^a   Dunn, William ^a   Law, Brian K ^a,c  

^a UNIVERSITY OF FLORIDA   (United States)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BETA CATENIN; CADHERIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYTOKERATIN 14; NESTIN; P CADHERIN; PROTEIN P120; UNCLASSIFIED DRUG; UVOMORULIN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; COLONY FORMATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; INJECTION; MAMMARY GLAND; MOUSE; MYOEPITHELIUM; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SPINDLE CELL; TRANSGENIC MOUSE;

EID: 55849145532     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.08710     Document Type: Article

References (62)

1. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98, 10869-10874.
2. Rakha EA, El-Rehim DA, Paish C, Green AR, Lee AH, Robertson JF, Blamey RW, Macmillan D, and Ellis IO (2006). Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer 42, 3149-3156.
3. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, et al. (2006). Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295, 2492-2502.
4. Li H, Cherukuri P, Li N, Cowling V, Spinella M, Cole M, Godwin AK, Wells W, and DiRenzo J (2007). Nestin is expressed in the basal/myoepithelial layer of the mammary gland and is a selective marker of basal epithelial breast tumors. Cancer Res 67, 501-510.
5. Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, Robertson JF, Nicholson RI, and Ellis IO (2004). Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 203, 661-671.
6. Dabbs DJ, Chivukula M, Carter G, and Bhargava R (2006). Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. Mod Pathol 19, 1506-1511.
7. McCarthy A, Savage K, Gabriel A, Naceur C, Reis-Filho JS, and Ashworth A (2007). A mouse model of basal-like breast carcinoma with metaplastic elements. J Pathol 211, 389-398.
8. Weaver Z, Montagna C, Xu X, Howard T, Gadina M, Brodie SG, Deng CX, and Ried T (2002). Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer. Oncogene 21, 5097-5107.
9. Poole AJ, Li Y, Kim Y, Lin SC, Lee WH, and Lee EY (2006). Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 314, 1467-1470.
10. Brodie SG, Xu X, Qiao W, Li WM, Cao L, and Deng CX (2001). Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice. Oncogene 20, 7514-7523.
11. Gauthier ML, Berman HK, Miller C, Kozakeiwicz K, Chew K, Moore D, Rabban J, Chen YY, Kerlikowske K, and Tlsty TD (2007). Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. Cancer Cell 12, 479-491.
12. Chytil A, Waltner-Law M, West R, Friedman D, Aakre M, Barker D, and Law B (2004). Construction of a cyclin D1-Cdk2 fusion protein to model the biological functions of cyclin D1-Cdk2 complexes. J Biol Chem 279, 47688-47698.
13. Corsino P, Davis B, Law M, Chytil A, Forrester E, Norgaard P, Teoh N, and Law B (2007). Tumors initiated by constitutive Cdk2 activation exhibit transforming growth factor beta resistance and acquire paracrine mitogenic stimulation during progression. Cancer Res 67, 3135-3144.
14. ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions. Oncogene 23, 3272-3283.
15. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, and Perou CM (2006). Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19, 264-271.
16. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, and Gong G (2006). Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol 37, 1217-1226.
17. Laakso M, Loman N, Borg A, and Isola J (2005). Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod Pathol 18, 1321-1328.
18. Maeda M, Johnson KR, and Wheelock MJ (2005). Cadherin switching: essential for behavioral but not morphological changes during an epithelium-to-mesenchyme transition. J Cell Sci 118, 873-887.
19. Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, and Palacios J (2008). Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 68, 989-997.
20. Warburton MJ, Ormerod EJ, Monaghan P, Ferns S, and Rudland PS (1981). Characterization of a myoepithelial cell line derived from a neonatal rat mammary gland. J Cell Biol 91, 827-836.
21. Zavizion B, Politis I, and Gorewit RC (1992). Bovine mammary myoepithelial cells: 2. Interactions with epithelial cells in vitro. J Dairy Sci 75, 3381-3393.
22. Zavizion B, Politis I, and Gorewit RC (1992). Bovine mammary myoepithelial cells: 1. Isolation, culture, and characterization. J Dairy Sci 75, 3367-3380.
23. Zavizion B, van Duffelen M, Schaeffer W, and Politis I (1996). Establishment and characterization of a bovine mammary myoepithelial cell line. In Vitro Cell Dev Biol Anim 32, 149-158.
24. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, et al. (2006). A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10, 515-527.
25. Katayose D, Gudas J, Nguyen H, Srivastava S, Cowan KH, and Seth P (1995). Cytotoxic effects of adenovirus-mediated wild-type p53 protein expression in normal and tumor mammary epithelial cells. Clin Cancer Res 1, 889-897.
26. Wang NP, To H, Lee WH, and Lee EY (1993). Tumor suppressor activity of RB and p53 genes in human breast carcinoma cells. Oncogene 8, 279-288.
27. Casey G, Lo-Hsueh M, Lopez ME, Vogelstein B, and Stanbridge EJ (1991). Growth suppression of human breast cancer cells by the introduction of a wildtype p53 gene. Oncogene 6, 1791-1797.
28. Schafer JM, Lee ES, O'Regan RM, Yao K, and Jordan VC (2000). Rapid development of tamoxifen-stimulated mutant p53 breast tumors (T47D) in athymic mice. Clin Cancer Res 6, 4373-4380.
29. Crawford AW, Michelsen JW, and Beckerle MC (1992). An interaction between zyxin and alpha-actinin. J Cell Biol 116, 1381-1393.
30. Maruyama K, Ochiai A, Nakamura S, Baba S, and Hirohashi S (1998). Dysfunction of E-cadherin-catenin system in invasion and metastasis of colorectal cancer. Nippon Geka Gakkai Zasshi 99, 402-408.
31. Nollet F, Berx G, and van Roy F (1999). The role of the E-cadherin/catenin adhesion complex in the development and progression of cancer. Mol Cell Biol Res Commun 2, 77-85.
32. Wong AS and Gumbiner BM (2003). Adhesion-independent mechanism for suppression of tumor cell invasion by E-cadherin. J Cell Biol 161, 1191-1203.
33. Bellovin DI, Bates RC, Muzikansky A, Rimm DL, and Mercurio AM (2005). Altered localization of p120 catenin during epithelial to mesenchymal transition of colon carcinoma is prognostic for aggressive disease. Cancer Res 65, 10938-10945.
34. ctn regulates the invasive phenotypes of E-cadherin-deficient breast cancer. Am J Pathol 164, 2269-2278.
35. Buckley MF, Sweeney KJ, Hamilton JA, Sini RL, Manning DL, Nicholson RI, deFazio A, Watts CK, Musgrove EA, and Sutherland RL (1993). Expression and amplification of cyclin genes in human breast cancer. Oncogene 8, 2127-2133.
36. Sutherland RL and Musgrove EA (2002). Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models. Breast Cancer Res 4, 14-17.
37. Foulkes WD, Brunet JS, Stefansson IM, Straume O, Chappuis PO, Begin LR, Hamel N, Goffin JR, Wong N, Trudel M, et al. (2004). The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular- proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 64, 830-835.
38. Loden M, Stighall M, Nielsen NH, Roos G, Emdin SO, Ostlund H, and Landberg G (2002). The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorogenesis based on pattern of genetic aberrations and inactivation of the pRb node. Oncogene 21, 4680-4690.
39. Brodie SG and Deng CX (2001). BRCA1-associated tumorigenesis: what have we learned from knockout mice? Trends Genet 17, S18-S22.
40. Hayami R, Sato K, Wu W, Nishikawa T, Hiroi J, Ohtani-Kaneko R, Fukuda M, and Ohta T (2005). Down-regulation of BRCA1-BARD1 ubiquitin ligase by CDK2. Cancer Res 65, 6-10.
41. Shakya R, Szabolcs M, McCarthy E, Ospina E, Basso K, Nandula S, Murty V, Baer R, and Ludwig T (2008). The basal-like mammary carcinomas induced by Brca1 or Bard1 inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppression. Proc Natl Acad Sci USA 105, 7040-7045.
42. Junk DJ, Vrba L, Watts GS, Oshiro MM, Martinez JD, and Futscher BW (2008). Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells. Neoplasia 10, 450-461.
43. Willenbring H, Sharma AD, Vogel A, Lee AY, Rothfuss A, Wang Z, Finegold M, and Grompe M (2008). Loss of p21 permits carcinogenesis from chronically damaged liver and kidney epithelial cells despite unchecked apoptosis. Cancer Cell 14, 59-67.
44. Sutherland RL and Musgrove EA (2004). Cyclins and breast cancer. J Mammary Gland Biol Neoplasia 9, 95-104.
45. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, and Schmidt EV (1994). Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369, 669-671.
46. Kong G, Chua SS, Yijun Y, Kittrell F, Moraes RC, Medina D, and Said TK (2002). Functional analysis of cyclin D2 and p27(Kip1) in cyclin D2 transgenic mouse mammary gland during development. Oncogene 21, 7214-7225.
47. Pirkmaier A, Dow R, Ganiatsas S, Waring P, Warren K, Thompson A, Hendley J, and Germain D (2003). Alternative mammary oncogenic pathways are induced by D-type cyclins; MMTV-cyclin D3 transgenic mice develop squamous cell carcinoma. Oncogene 22, 4425-4433.
48. Laakso M, Tanner M, Nilsson J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmstrom P, Wilking N, Bergh J, and Isola J (2006). Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin Cancer Res 12, 4185-4191.
49. Asano-Miyoshi M, Hamamichi R, and Emori Y (2008). Cytokeratin 14 is expressed in immature cells in rat taste buds. J Mol Histol 39, 193-199.
50. Wu PC, Lai VC, Fang JW, Gerber MA, Lai CL, and Lau JY (1999). Hepatocellular carcinoma expressing both hepatocellular and biliary markers also expresses cytokeratin 14, a marker of bipotential progenitor cells. J Hepatol 31, 965-966.
51. Li L, Mignone J, Yang M, Matic M, Penman S, Enikolopov G, and Hoffman RM (2003). Nestin expression in hair follicle sheath progenitor cells. Proc Natl Acad Sci USA 100, 9958-9961.
52. Carriere C, Seeley ES, Goetze T, Longnecker DS, and Korc M (2007). The nestin progenitor lineage is the compartment of origin for pancreatic intra-epithelial neoplasia. Proc Natl Acad Sci USA 104, 4437-4442.
53. Wiese C, Rolletschek A, Kania G, Blyszczuk P, Tarasov KV, Tarasova Y, Wersto RP, Boheler KR, and Wobus AM (2004). Nestin expression - a property of multi-lineage progenitor cells? Cell Mol Life Sci 61, 2510-2522.
54. Kleeberger W, Bova GS, Nielsen ME, Herawi M, Chuang AY, Epstein JI, and Berman DM (2007). Roles for the stem cell associated intermediate filament nestin in prostate cancer migration and metastasis. Cancer Res 67, 9199-9206.
55. Sy SM, Lai PB, Pang E, Wong NL, To KF, Johnson PJ, and Wong N (2006). Novel identification of zyxin upregulations in the motile phenotype of hepatocellular carcinoma. Mod Pathol 19, 1108-1116.
56. Arima Y, Inoue Y, Shibata T, Hayashi H, Nagano O, Saya H, and Taya Y (2008). Rb depletion results in deregulation of E-cadherin and induction of cellular phenotypic changes that are characteristic of the epithelial-to- mesenchymal transition. Cancer Res 68, 5104-5112.
57. Xie L, Law BK, Chytil AM, Brown KA, Aakre ME, and Moses HL (2004). Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro. Neoplasia 6, 603-610.
58. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, et al. (2007). Molecular definition of breast tumor heterogeneity. Cancer Cell 11, 259-273.
59. - breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 8, R59.
60. - phenotype is enriched in basal-like breast tumors. Breast Cancer Res 10, R53.
61. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, Kehrl JH, et al. (1986). Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 83, 4167-4171.
62. Lohr M, Schmidt C, Ringel J, Kluth M, Muller P, Nizze H, and Jesnowski R (2001). Transforming growth factor-beta1 induces desmoplasia in an experimental model of human pancreatic carcinoma. Cancer Res 61, 550-555.